Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | CA9 | Q16790 | 4/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | F11 | P03951 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5683251 | 0.95 | CA2 (0.56) | CA2CA9CA1KMT2ALMNA | |
| SCHEMBL3672101 | 0.95 | CA2 (0.56) | CA2CA9CA1KMT2ALMNA | |
| Silver SCHEMBL31590866 | 0.95 | CA2 (0.56) | CA2CA9CA1KMT2ALMNA | |
| SCHEMBL17456527 | 0.95 | CA2 (0.56) | CA2CA9CA1KMT2ALMNA | |
| SCHEMBL8058038 | 0.95 | CA2 (0.56) | CA2CA9CA1KMT2ALMNA | |
| Lithium Ion SCHEMBL812224 | 0.95 | CA2 (0.56) | CA2CA9CA1KMT2ALMNA | |
| Potassium Ion SCHEMBL10359278 | 0.95 | CA2 (0.56) | CA2CA9CA1KMT2ALMNA | |
| SCHEMBL8741911 | 0.95 | CA2 (0.56) | CA2CA9CA1KMT2ALMNA | |
| SCHEMBL28037495 | 0.95 | CA2 (0.56) | CA2CA9CA1KMT2ALMNA | |
| SCHEMBL666853 | 0.95 | CA1 (0.56) | CA2CA9CA1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 578 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998111-A1 | USE OF A ZINC CARBOXYLATE SALT TO IMPROVE PERFORMANCE OF A DEODORANT COMPOSITION | Givaudan SA (CH) | 2022-05-18 | — | — | EP | claimed |
| US-20080213191-A1 | Composition and/or articles comprising cyclodextrin complexing material | PROCTER & GAMBLE COMPANY, THE | 2008-09-04 | — | — | US | claimed |
| EP-1185238-B1 | DEODORANT COMPOSITIONS CONTAINING CYCLODEXTRIN ODOR CONTROLLING AGENTS | PROCTER & GAMBLE (US) | 2005-10-19 | — | — | EP | claimed |
| EP-1185238-A1 | DEODORANT COMPOSITIONS CONTAINING CYCLODEXTRIN ODOR CONTROLLING AGENTS | The Procter & Gamble Company (US) | 2002-03-13 | — | — | EP | claimed |
| WO-2002013776-A2 | METHOD OF PROVIDING IMPROVED DEODORANT APPLICATION TO THE UNDERARM | THE PROCTER & GAMBLE COMPANY (US) | 2002-02-21 | — | — | WO | claimed |
| WO-2000076471-A1 | DEODORANT COMPOSITIONS CONTAINING CYCLODEXTRIN ODOR CONTROLLING AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2000-12-21 | — | — | WO | claimed |
| US-6123932-A | AN AQUEOUS DEODORANT COMPRISING A CYCLODEXTRIN, A SOLID NONPOLYMERIC GELLANT FREE OF INORGANIC GELLING AGENT AND WATER, USEFUL FOR CONTROLLING MALODORS ASSOCIATED WITH HUMAN PERSPIRATION | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-26 | — | — | US | claimed |
| WO-1997027862-A1 | SUPPLEMENTATION OF GLUCOCORTICOIDS | BELLARA MEDICAL PRODUCTS LIMITED (AU) | 1997-08-07 | — | — | WO | claimed |
| WO-1995025513-A1 | ZINC COMPOUND AND CYCLODEXTRINE FOR TREATMENT OF GASTRIC DISORDERS | BELLARA MEDICAL PRODUCTS LIMITED (AU) | 1995-09-28 | — | — | WO | claimed |
| US-20240238624-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING CAPSULES | PROCTER & GAMBLE (US) | 2024-07-18 | — | — | US | disclosed |
| US-12016943-B2 | Antiperspirant or deodorant composition | FIRMENICH SA (CH) | 2024-06-25 | — | — | US | disclosed |
| EP-3856130-B1 | ANTIPERSPIRANT OR DEODORANT COMPOSITION | FIRMENICH & CIE (CH) | 2024-06-12 | — | — | EP | disclosed |
| CN-118078649-A | Microcapsules, method for preparing same, and non-cosmetic composition comprising a plurality of microcapsules | 塔格拉生物技术有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4362888-A1 | FAST DRYING PERFUME COMPOSITION | Firmenich SA (CH) | 2024-05-08 | — | — | EP | disclosed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | disclosed |
| US-4256731-A | COMPRISING A CATIONIC MICROBIOCIDE AND A QUATERNARY AMMONIUM COMPOUND ALONG WITH INHIBITION DISCOLORATION-COMPOUNDS WHICH INCLUDE A NONIONIC SURFACTANT AND AN AMINO ACID OR A DI- OR TRICARBOXYLIC ACID | BEECHAM, INC. (US) | 1981-03-17 | — | — | US | disclosed |
| US-4213961-A | Oral compositions | BEECHAM, INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4154815-A | Zinc and enzyme toothpowder dentifrice | LEVER BROTHERS COMPANY (US) | 1979-05-15 | — | — | US | disclosed |
| US-4152418-A | Zinc and enzyme mouthwash and mouthwash concentrate for reducing dental plaque and calculus formation | LEVER BROTHERS COMPANY (US) | 1979-05-01 | — | — | US | disclosed |
| US-4082841-A | ZINC SALT AND AN ENZYME | LEVER BROTHERS COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016943-B2 | Antiperspirant or deodorant composition | LPO, SIGMAR1, DEK | CA2 4236/4885CA9 2499/4885CA1 4523/4885 |
| US-20240238624-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING CAPSULES | DDT, QDPR, DDX5 | CA2 1495/4885CA9 674/4885CA1 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.